Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size
30 studies found for:    " July 20, 2011":" August 19, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Terminated Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy
Conditions: Human Immunodeficiency Virus;   Lipohypertrophy
Intervention: Drug: Raltegravir-Maraviroc
2 Recruiting Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV
Condition: HIV-infection
Intervention: Drug: Angiotensin II Infusion
3 Completed A Safety Study Of A Single Vaginal Administration Of P2G12 Antibody In Healthy Female Subjects
Condition: Human Immunodeficiency Virus
Intervention: Drug: P2G12
4 Completed
Has Results 		Home Assessment and Initiation of Antiretroviral Therapy for HIV in Malawi
Condition: HIV
Interventions: Other: Home assessment and initiation of ART;   Other: Clinic-based ART assessment and initiation
5 Recruiting Allogeneic Transplant in HIV Patients (BMT CTN 0903)
Conditions: Leukemia;   Lymphoma;   HIV
Interventions: Drug: Fludarabine and Busulfan;   Drug: Fludarabine and Melphalan;   Drug: Busulfan and Fludarabine;   Drug: Cyclophosphamide and Total Body Irradiation
6 Completed Moringa Oleifera- Antiretroviral Pharmacokinetic Drug Interaction
Condition: HIV
Intervention: Dietary Supplement: Moringa oleifera
7 Completed Safety and Immunogenicity Study of a DNA Priming and MVA Boosting Strategy of HIV Vaccine
Condition: HIV Infections
Interventions: Biological: DNA HIVIS and MVA-CMDR;   Biological: Saline solution
8 Unknown † HEART to HAART: Smartphone Intervention to Improve HAART Adherence for Drug Users
Conditions: HIV;   Drug Use Disorders
Interventions: Behavioral: HEART to HAART;   Behavioral: adherence counseling with the addition of smartphone control
9 Unknown † Depression and ART Adherence in HIV+ Latinos
Conditions: Depressive Symptoms;   HIV Infections
Intervention: Behavioral: Cognitive-Behavioral Therapy AD
10 Completed Drug Interaction Study Between Dolutegravir and Prednisone
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: Dolutegravir;   Drug: Prednisone
11 Recruiting Eplerenone in HIV Associated Abdominal Fat Accumulation
Condition: HIV
Interventions: Drug: Eplerenone and lifestyle;   Other: placebo and lifestyle
12 Active, not recruiting Effectiveness of Peer Navigation to Link Released HIV+ Jail Inmates to HIV Care
Condition: HIV-infection/Aids
Intervention: Behavioral: Health Navigator
13 Completed
Has Results 		Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects
Condition: HIV
Interventions: Drug: Atazanavir (current formulation);   Drug: Atazanavir, powder for oral use 1  (POU1);   Drug: Atazanavir (POU2)
14 Completed
Has Results 		Lower Extremity Splinting to Manage Pain and Sleep Disturbances Associated With HIV/AIDS Related Peripheral Neuropathy
Conditions: HIV;   AIDS;   Peripheral Neuropathy;   Pain;   Sleep
Interventions: Device: Splinting application to the lower extremities;   Device: Splint liner application
15 Recruiting Integrated Stepped Care for Unhealthy Alcohol Use in HIV
Conditions: Liver Diseases, Alcoholic;   Alcoholism;   HIV;   Hepatitis C
Interventions: Other: Integrated Stepped Care (ISC);   Other: Treatment as Usual
16 Active, not recruiting Adolescent Master Protocol
Condition: HIV/AIDS
Intervention:
17 Unknown † Centralized Off-Site Adherence Enhancement Program
Condition: HIV/AIDS
Intervention: Behavioral: cognitive-behavioral therapy
18 Recruiting the " Extreme " Cohort (CODEX)
Condition: HIV Infection
Intervention: Biological: blood sampling
19 Terminated Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment
Conditions: HIV Infection;   Tuberculosis
Interventions: Drug: Experimental: Empiric TB treatment;   Drug: ART only arm
20 Active, not recruiting Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use
Condition: HIV Prevention
Interventions: Drug: Tenofovir 1% vaginal gel;   Drug: Depo-medroxyprogesterone acetate (DMPA);   Drug: Oral contraceptive: LNG 150 mcg and EE 30 mcg
To Top

   Previous Page Studies Shown (1-20) Next Page (21-30) Show next page of results    Last Page
† Indicates status has not been verified in more than two years